Five-year survival and prognostic factors for oropharyngeal squamous cell carcinoma: retrospective cohort of a cancer center
| Autor: | Edilmar de Moura Santos, Joaquim Felipe Junior, Weslay Rodrigues da Silva, Cristianne Kalinne Santos Medeiros, Glória Maria de França, Hébel Cavalcanti Galvão |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Oncology
Male medicine.medical_specialty medicine.medical_treatment Population Internal medicine Adjuvant therapy Medicine Humans Stage (cooking) education Aged Retrospective Studies education.field_of_study business.industry Squamous Cell Carcinoma of Head and Neck Head and neck cancer Cancer Retrospective cohort study Middle Aged medicine.disease Prognosis Radiation therapy Oropharyngeal Neoplasms Otorhinolaryngology Head and Neck Neoplasms Cohort Carcinoma Squamous Cell Surgery Female Oral Surgery business |
| Zdroj: | Oral and maxillofacial surgery. 26(2) |
| ISSN: | 1865-1569 |
| Popis: | Oropharyngeal cancer is characterized by high morbidity and mortality. Prognostic factors for this cancer are therefore useful to predict overall survival and may provide additional therapeutic targets.To evaluate the 5-year overall survival and prognostic factors for oropharyngeal squamous cell carcinoma.Retrospective cohort (2008-2018) of a cancer referral center. The population of the study was a hospital-based cohort consisting of patients diagnosed with oropharyngeal cancer who underwent surgery and/or adjuvant therapy (radio- and/or chemotherapy).A total of 253 patients with oropharyngeal squamous cell carcinoma were analyzed. The mean age was 59.8 ± 11.9 years and there was a male predominance (81.8%). Smoking and alcohol consumption were found in 88.0% and 84.2% of the sample, respectively. The combination of radiotherapy and chemotherapy was the treatment modality in 42.7% of the sample, followed by surgery combined with radio- and chemotherapy in 15.8%. There were 143 deaths (events), the mean survival was 11.55 ± 9.69 months, and the 5-year overall survival rate was 1.1%. Overall survival was lower for clinical stage III/IV (p 0.001), HPV p16-negative status (p = 0.019), and an interval 4 weeks between diagnosis and the beginning of treatment (p 0.007).Among the prognostic factors analyzed in this cohort, p16-negative status as a poor prognostic indicator and tumor stage III/IV and an interval longer than 4 weeks between diagnosis and the beginning of treatment were significantly associated with lower overall survival. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink